Concepedia

Risk of multiple sclerosis relapses when switching from fingolimod to cell-depleting agents: the role of washout duration

Diana Ferraro, Pietro Iaffaldano, Tommaso Guerra, Matilde Inglese, Marco Capobianco, Vincenzo Brescia Morra, Mauro Zaffaroni, Massimiliano Mirabella, Giacomo Lus, Francesco Patti,

Journal of Neurology · 2021 · 10 citations · 19 references

DOI

Concepts

References

19

FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis

Matthias Mehling, Volker Brinkmann, Jack P. Antel et al. · Neurology · 2008 · 343 citations

, , +17

Rebound Syndrome in Patients With Multiple Sclerosis After Cessation of Fingolimod Treatment

Stacy E. Hatcher, Emmanuelle Waubant, Bardia Nourbakhsh et al. · JAMA Neurology · 2016 · 213 citations · Full text

, , +13

Fingolimod after natalizumab and the risk of short-term relapse

Vilija Jokubaitis, Vivien Li, Tomáš Kalinčík et al. · Neurology · 2014 · 141 citations

, , +15

Switching From Natalizumab to Fingolimod in Multiple Sclerosis

Mikaël Cohen, Élisabeth Maillart, Ayman Tourbah et al. · JAMA Neurology · 2014 · 140 citations

, , +16

Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy

G. Francis, Ludwig Kappos, Paul O’Connor et al. · Multiple Sclerosis Journal · 2013 · 134 citations

, , +15